Antiplatelet Use in Ischemic Stroke Inpatients: A Single-Centre Retrospective Study

Nailis Syifa', Nala Salma Nabila, Didik Hasmono, Rani Nur Badriyah

Abstract


Stroke is an acute neurological condition caused by interruption of blood flow to the brain, spinal cord, or retina, leading to disability or death. Ischemic stroke is the most common type and is closely related to thrombosis or embolism in cerebral vessels. Antiplatelet agents are central to secondary prevention because they inhibit platelet aggregation and thrombus formation, thereby reducing the risk of recurrent stroke. This study aimed to describe the pattern of antiplatelet use among ischemic stroke inpatients at Dr. Saiful Anwar Malang Regional General Hospital. This was an observational, single-centre, retrospective descriptive study using medical records of ischemic stroke inpatients who received at least one antiplatelet regimen and had complete data between January and December 2024. Patients with incomplete records, without antiplatelet therapy during hospitalization, or with uncertain diagnoses were excluded. Data were analysed descriptively. Of 190 patients diagnosed with ischemic stroke, 124 met the eligibility criteria. Overall, 153 antiplatelet regimens were identified: 118 (77.1%) single-antiplatelet regimens and 35 (22.9%) dual-antiplatelet regimens. The most common single regimen was aspirin 160 mg once daily by mouth (70/118; 59.3%), followed by aspirin 160 mg once daily via nasogastric tube (24/118; 20.3%). The most frequent dual-antiplatelet regimen was aspirin 80 mg once daily by mouth plus clopidogrel 75 mg once daily by mouth (30/35; 85.7%). There were 17 regimen switches during hospitalization, most often from aspirin 160 mg once daily to aspirin 80 mg once daily (3/17; 17.6%), reflecting adjustment from the acute to the maintenance phase. In conclusion, single antiplatelet therapy, predominantly aspirin 160 mg once daily, was more commonly used than dual antiplatelet therapy among ischemic stroke inpatients in this hospital. These findings describe real-world prescribing patterns and may support evaluation of local protocols and future outcome-based studies.

Keywords


Ischemic stroke; Antiplatelet Therapy; Aspirin; Clopidogrel; Inpatient Care

Full Text:

PDF

References


J. T. DiPiro, G. C. Yee, S. T. Haines, T. D. Nolin, V. L. Ellingrod, and L. M. Posey, Pharmacotherapy: A Pathophysiologic Approach, 12th ed. New York, NY, USA: McGraw Hill, 2023. [Online]. Available: https://accesspharmacy.mhmedical.com/content.aspx?aid=1201057727

V. L. Feigin et al., “World Stroke Organization: Global Stroke Fact Sheet 2025,” Int. J. Stroke, vol. 20, no. 2, pp. 132–144, 2025. [Online]. Available: https://doi.org/10.1177/17474930241308142

Ministry of Health, Republic of Indonesia (BKPK), “Survei Kesehatan Indonesia (SKI) 2023,” 2023. [Online]. Available: https://www.badankebijakan.kemkes.go.id/hasil-ski-2023/

Ministry of Health, Republic of Indonesia, “Pedoman Nasional Pelayanan Kedokteran (PNPK) – Tata Laksana Stroke,” 2019. [Online]. Available: https://kemkes.go.id/id/pnpk-2019---tata-laksana-stroke

(AHA/ASA overview requested) “2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack,” Stroke, vol. 52, 2021. [Online]. Available: https://www.guidelinecentral.com/guideline/7086/

G. Gelbenegger and B. Jilma, “Clinical pharmacology of antiplatelet drugs,” Expert Rev. Clin. Pharmacol., vol. 15, no. 10, pp. 1177–1197, 2022. [Online]. Available: https://doi.org/10.1080/17512433.2022.2121702

D. R. Kurniasari, “Evaluation of the rational use of antiplatelet drugs in ischemic-stroke inpatients at Dr. Moewardi Hospital, Surakarta, 2016,” Undergraduate thesis, 2017. [Online]. Available: https://eprints.ums.ac.id/58576/10/Naskah%20Publikasi.pdf

S. Megawati, R. Rahayu, and N. Fhatonah, “Evaluation of antiplatelet use in ischemic stroke inpatients at Tangerang District Hospital, 2019,” J. Farmagazine, vol. 8, 2021. [Online]. Available: http://dx.doi.org/10.47653/farm.v8i1.531

Samirah, R. A. Safitri, A. Machsin, Suharjono, and N. R. Zanuba, “Drug utilization study of antiplatelet in thrombotic stroke patients,” Journal of Pharmacy and Science, vol. 10, no. 2, pp. 191–196, 2025. [Online]. Available: https://doi.org/10.53342/pharmasci.v10i2.483

A. Gracias and L. Doris, “Gender differences in stroke risk and recovery,” Stroke, 2024. [Online]. Available: https://www.researchgate.net/publication/386099172_GENDER_DIFFERENCES_IN_STROKE_RISK_AND_RECOVERY

W. Wang, F. Han, C. Qu, and P. Sun, “Sex differences in risk factors for transient ischemic attack in a Chinese population,” Front. Neurol., vol. 12, 2021. [Online]. Available: https://doi.org/10.3389/fneur.2021.615399

S. A. Vivi and N. Fitri, “Association of age, sex, and stroke type with quality of life among stroke patients,” J. Penelitian Keperawatan, vol. 11, 2025. [Online]. Available: https://doi.org/10.32660/jpk.v11i1.804

A. C. I. P. Zendrato and N. Barus, “Profile and management of ischemic stroke inpatients at RSU Royal Prima Medan, 2019,” J. Kedokteran STM, vol. 4, no. 1, pp. 1–9, 2021. [Online]. Available: https://doi.org/10.30743/stm.v4i1.63

P. N. Puspitasari, “Association of hypertension with stroke incidence,” J. Ilmiah Kesehatan Sandi Husada, vol. 12, 2020. [Online]. Available: https://doi.org/10.35816/jiskh.v12i2.435

N. Kesuma, D. Krismashogi, and H. Fatmawati, “Risk factors and ischemic-stroke risk level using the stroke risk scorecard at RSUD Klungkung,” Intisari Sains Medis, vol. 10, 2019. [Online]. Available: https://doi.org/10.15562/ism.v10i3.397

D. O. Kleindorfer et al., “2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack,” Stroke, vol. 52, 2021. [Online]. Available: https://doi.org/10.1161/STR.0000000000000375

R. Ariani, L. Amalia, S. Gunadharma, and K. Anggadiredja, “Efficacy and adverse drug reaction monitoring of antiplatelet therapy in post-ischemic-stroke patients at Dr. Hasan Sadikin General Hospital,” J. Sains dan Kesehatan, vol. 5, pp. 850–859, 2023. [Online]. Available: https://doi.org/10.25026/jsk.v5i5.1944

I. A. Solihah, A. Pebiansyah, and I. Amelia, “Recurrent ischemic stroke in patients on antiplatelet therapy at SMC Tasikmalaya Hospital,” in Proc. Seminar Nasional Diseminasi Penelitian, 2024. https://ejurnal.universitas-bth.ac.id/index.php/conference/article/view/1499/1116

W. J. Powers et al., “Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines,” Stroke, vol. 50, 2019. [Online]. Available: https://doi.org/10.1161/STR.0000000000000211

R. A. A. Putri et al., “Use of dual antiplatelet therapy in ischemic stroke with prior coronary artery disease,” MAHESA, vol. 4, 2024. [Online]. Available: https://doi.org/10.33024/mahesa.v4i12.16289

S. Octariani, D. Mayasari, and A. Ramadhan, “Aspirin–clopidogrel combination vs. aspirin alone in ischemic stroke: a literature review,” in Proc. Mulawarman Pharmaceuticals Conferences, vol. 14, pp. 405–412, 2021. [Online]. Available: https://doi.org/10.25026/mpc.v14i1.597

A. J. Ansara, S. A. Nisly, S. A. Arif, J. M. Koehler, and S. T. Nordmeyer, “Aspirin dosing for the prevention and treatment of ischemic stroke: An indication-specific review of the literature,” Ann. Pharmacother., vol. 44, no. 5, pp. 851–862, 2010. [Online]. Available: http://dx.doi.org/10.1345/aph.1M346

Vitria, “Use of antiplatelets for secondary prevention of ischemic stroke and acute coronary syndrome in Indonesia: a literature review,” Undergraduate thesis, Universitas Islam Indonesia, 2022. [Online]. Available: https://dspace.uii.ac.id/bitstream/handle/123456789/38403/17613063.pdf?sequence=1&isAllowed=y




DOI: https://doi.org/10.37311/ijpe.v5i3.34158

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Nailis Syifa', Nala Salma Nabila, Didik Hasmono, Rani Nur Badriyah

Creative Commons License
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.